Cytek Biosciences, Inc.
CTKB
$4.28
-$0.09-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 18.83% | 14.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.83% | 14.67% | |||
| Cost of Revenue | 18.24% | 13.83% | |||
| Gross Profit | 19.36% | 15.44% | |||
| SG&A Expenses | 6.23% | 8.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.17% | 9.35% | |||
| Operating Income | 39.14% | 13.48% | |||
| Income Before Tax | 48.11% | -14.67% | |||
| Income Tax Expenses | 1,847.93% | -92.20% | |||
| Earnings from Continuing Operations | -704.60% | 1.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -704.60% | 1.88% | |||
| EBIT | 39.14% | 13.48% | |||
| EBITDA | 49.16% | 16.72% | |||
| EPS Basic | -701.63% | 2.50% | |||
| Normalized Basic EPS | 48.29% | -14.07% | |||
| EPS Diluted | -701.63% | 2.50% | |||
| Normalized Diluted EPS | 48.29% | -14.07% | |||
| Average Basic Shares Outstanding | 0.48% | 0.48% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||